30 closest matches · ranked by relevance
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Brain Tumor · Central Nervous System Tumors · Childhood Germ Cell Tumor
Primary: Response to Induction Chemotherapy — 74; 11 Participants
Extragonadal Germ Cell Tumor · Ovarian Cancer · Testicular Germ Cell Tumor
Primary: Overall Objective Response — 50; 4; 36; 8 participants
Testicular Cancer
Primary: Number of Participants With 2-year Event-Free Survival (EFS) — 28; 11 Participants
Neoplasms, Germ Cell and Embryonal
Primary: Twelve Month Disease-free Survival Rate — 3.5 percentage of participants
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Rate of Complete Response — 38; 7; 11 Participants
Extragonadal Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Confirmed Objective Response Rate (Complete and Partial Response) as Measured by RECIST Criteria After 2 Courses of Treatment — 3; 7 participants
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Progression-free Survival — 11.8 Months
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Extragonadal Germ Cell Tumor · Teratoma · Testicular Germ Cell Tumor
Primary: Progression-free Survival Rate After 1 Course of Treatment — 48; 59 percentage of participants — p=0.05
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Response — 12; 6; 5 participants
Recurrent Extragonadal Seminoma · Recurrent Malignant Extragonadal Germ Cell Tumor · Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
Primary: Objective Response Rate — 0; 6; 2; 10 participants
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 1; 1; 0; 0 participants
Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Malignant Germ Cell Tumor · Childhood Malignant Ovarian Germ Cell Tumor
Primary: Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 12; 8 participants
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting — 29.6; 46.3; 24.1 percentage of participants
Malignant Ovarian Epithelial Tumor · Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma
Primary: Tumor Response — 16.7 percentage of patients
Germ Cell Tumors
Primary: Complete Response. — 47; 15 percentage of evaluable subjects
Incurable Platinum Refractory Germ Cell Tumors · Tumors
Primary: Recommended Phase 2 Dose (RP2D) of ASP1650 — 1500 Milligram per meter square (mg/m^2)
Childhood Atypical Teratoid/Rhabdoid Tumor
Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants
Localized Extraskeletal Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor of Bone · Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Primary: Event-Free Survival — 77.64; 78.79 Percent Probability
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Objective Tumor Response — 21; 32; 17; 1 participants
Extraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 88; 83; 28 Probability
Sarcoma
Primary: Overall Objective Response — 4; 1 participants
Metastatic Seminoma
Primary: 2 - Year Progression Free Survival — 46 Participants
Ovarian Cancer
Primary: Adverse Events Related to Study Treatment — 5 Participants
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants